Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 6;22(1):2.
doi: 10.1007/s11934-020-01021-x.

From Diagnosis to Therapy-PET Imaging for Pheochromocytomas and Paragangliomas

Hiren V Patel  1 , Arnav Srivastava  1 , Murray D Becker  2 , Toni Beninato  3 , Amanda M Laird  3 , Eric A Singer  4
Affiliations
Review

From Diagnosis to Therapy-PET Imaging for Pheochromocytomas and Paragangliomas

Hiren V Patel et al. Curr Urol Rep. .

Abstract

Purpose of review: Pheochromocytoma and paraganglioma (PPGLs) are neuroendocrine tumors with diverse clinical presentations. PPGLs can be sporadic but often are associated with various syndromes, which can have variable clinical presentations. A thorough workup is therefore critical for staging, treatment, and follow-up. Imaging is an essential part of the workup and diagnosis of PPGLs.

Recent findings: Improvements in cross-sectional imaging with radionuclides have increased specificity and sensitivity for identifying and treating PPGLs. Furthermore, a variety of targets on PPGLs has allowed for optimal imaging with radionuclides that can be used for staging and treatment. Currently, radionuclides are being evaluated for staging and treatment of PPGLs. Developing novel radionuclides that can identify disease sites and target them simultaneously provides a potential for improving survival and outcomes in patients with PPGLs. Given the clinical diversity among PPGLs, expanding the therapeutic arsenal against locally advanced or metastatic PPGLs can allow clinicians to evaluate and treat PPGLs thoroughly.

Keywords: PET imaging; Paragangliomas; Pheochromocytomas; Radiotracers.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915–42. https://doi.org/10.1210/jc.2014-1498 . - DOI - PubMed - PMC
    1. Baguet JP, Hammer L, Mazzuco TL, Chabre O, Mallion JM, Sturm N, et al. Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients. Eur J Endocrinol. 2004;150(5):681–6. - DOI
    1. Kopetschke R, Slisko M, Kilisli A, Tuschy U, Wallaschofski H, Fassnacht M, et al. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol. 2009;161(2):355–61. https://doi.org/10.1530/EJE-09-0384 . - DOI - PubMed
    1. Wen J, Li HZ, Ji ZG, Mao QZ, Shi BB, Yan WG. A decade of clinical experience with extra-adrenal paragangliomas of retroperitoneum: report of 67 cases and a literature review. Urol Ann. 2010;2(1):12–6. https://doi.org/10.4103/0974-7796.62919 . - DOI - PubMed - PMC
    1. Somasundar P, Krouse R, Hostetter R, Vaughan R, Covey T. Paragangliomas--a decade of clinical experience. J Surg Oncol. 2000;74(4):286–90. https://doi.org/10.1002/1096-9098(200008)74:4<286::aid-jso9>3.0.co... . - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources